










Prescription Drug Advisory Boards: **Where They Are and Why They Matter to Patients**

[PART 2]

Why are Some “High-Cost” Therapies Targeted by PDABs

PDABs are increasingly targeting life-saving medications, including those for rare diseases and those related to public health initiatives, like Cancer and HIV medications and Hepatitis C cures. While well-intended, **the impacts of these actions threaten the patient-provider relationship** and the funding safety-net providers rely upon to provide **timely, appropriate life-saving care**.

Here's a look at how many patients might be negatively impacted by PDABs:

| | | | Cancer | HIV | Hepatitis C Total |
|-----------|-------------------------------------------------------------------------------------|---------------|---------------|------------|--------------------------|
| CO |  | Colorado | 24,280 | 13,442 | 1,840 |
| ME |  | Maine | 9,151 | 1,693 | 840 |
| MD |  | Maryland | 30,603 | 33,467 | 2,202 |
| MN |  | Minnesota | 30,505 | 9,223 | 908 |
| NH |  | New Hampshire | 8,177 | 1,365 | 50 |
| NJ |  | New Jersey | 50,346 | 35,207 | 2,461 |
| OH |  | Ohio | 65,151 | 24,084 | 6,829 |
| OR |  | Oregon | 20,141 | 7,484 | 1,678 |
| WA |  | Washington | 36,017 | 14,591 | 2,678 |

Sources:

[CDC Cancer Link](#) | [CDC HIV Link](#) | [CDC HCV - Chronic](#) | [CDC HCV - Perinatal](#) | [CDC HCV - Acute](#)